The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in
infants who are at risk for an exchange transfusion and meet the criteria of the protocol.
Phase:
Phase 2
Details
Lead Sponsor:
InfaCare Pharmaceuticals Corporation InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Collaborators:
National Children's Hospital, Vietnam National Hospital of Pediatrics, Vietnam